Greene M I, Dorf M E, Pierres M, Benacerraf B
Proc Natl Acad Sci U S A. 1977 Nov;74(11):5118-21. doi: 10.1073/pnas.74.11.5118.
Highly significant suppression of the growth of S1509a and Sa-I syngeneic sarcomas was observed in A/J mice following daily intravenous injections of 2 microliter of anti-I-Jk alloantiserum. This effect persisted as long as the anti-I-Jk serum was administered (day 15), In contrast, a control anti-I-Js serum had no discernible effect on the growth of the S1509a tumor. The inhibitory activity of the anti-I-Jk serum on the growth of the tumor was absorbed specifically by B10-BR spleen cells bearing I-Jk determinants. In other experiments, we established that A/J mice treated with anti-I-Jk serum, according to the protocol described above, are no longer a source of tumor-specific suppressor cells for adoptive transfer into immune tumor-bearing recipient mice. We conclude that anti-I-Jk serum inhibits tumor growth in A/J mice by abolishing tumor-specific suppressor activity.
在A/J小鼠中,每天静脉注射2微升抗I-Jk同种异体抗血清后,观察到S1509a和Sa-I同基因肉瘤的生长受到高度显著抑制。只要给予抗I-Jk血清(第15天),这种效果就会持续。相比之下,对照抗I-Js血清对S1509a肿瘤的生长没有明显影响。抗I-Jk血清对肿瘤生长的抑制活性被携带I-Jk决定簇的B10-BR脾细胞特异性吸收。在其他实验中,我们确定,按照上述方案用抗I-Jk血清处理的A/J小鼠不再是用于过继转移到免疫的荷瘤受体小鼠中的肿瘤特异性抑制细胞的来源。我们得出结论,抗I-Jk血清通过消除肿瘤特异性抑制活性来抑制A/J小鼠中的肿瘤生长。